Amelioration of Systemic Amyloidosis by Blocking IL-17A and Not by IL-17F, and Arteriosclerosis by Blocking Both IL-17A and IL-17F in an Inflammatory Skin Mouse Model
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Inflammatory skin conditions like atopic dermatitis and psoriasis are linked to serious health issues. Targeting Interleukin-17A (IL-17A) and IL-17F may reduce organ damage and improve life expectancy in affected patients.
Area Of Science
- Immunodermatology
- Vascular Biology
- Pathogenesis of Inflammatory Diseases
Background
- Atopic dermatitis and psoriasis are linked to comorbidities like arteriosclerosis and amyloidosis, reducing life expectancy.
- Inflammatory cytokines released by the skin can cause systemic inflammation and damage internal organs.
- Biological treatments targeting Interleukin-17 (IL-17) show promise for managing these conditions and their complications.
Purpose Of The Study
- To investigate the role of IL-17A and IL-17F in the development of visceral complications associated with dermatitis.
- To evaluate the efficacy of IL-17A and IL-17F inhibition in preventing organ damage in a dermatitis mouse model.
Main Methods
- Utilized a long-lasting dermatitis mouse model (Kcasp1Tg) overexpressing human caspase-1 in keratinocytes.
- Cross-mated Kcasp1Tg mice with IL-17A-, IL-17F-, and IL-17A/F-deficient mice.
- Assessed skin and visceral organs histologically and analyzed aortic sclerosis markers via RT-PCR.
Main Results
- Deletion of IL-17A reduced multiple organ amyloidosis in Kcasp1Tg mice, despite minimal improvement in dermatitis.
- Aortic sclerosis was reduced in mice lacking both IL-17A and IL-17F.
- IL-17A and IL-17F demonstrated varied effects on organ damage depending on the specific organ.
Conclusions
- Inhibition of IL-17A and IL-17F may reduce the risk of developing internal organ comorbidities associated with dermatitis.
- Targeting IL-17 cytokines offers a potential therapeutic strategy for managing systemic complications of inflammatory skin diseases.
- Further research is needed to clarify the distinct roles of IL-17A and IL-17F in preventing late-stage organ damage.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
